[Skip to Content]
[Skip to Content Landing]
Correspondence
September 2005

Rosaceiform Dermatitis as a Complication of Treatment of Facial Seborrheic Dermatitis With 1% Pimecrolimus Cream

Author Affiliations
 

Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005

Arch Dermatol. 2005;141(9):1168. doi:10.1001/archderm.141.9.1168

Antille et al1 recently reported a case of rosaceiform dermatitis as a complication of treatment of inflammatory dermatoses with topical tacrolimus. We report a case of rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream.

A 36-year-old man was referred for evaluation of moderate facial seborrheic dermatitis. The patient applied 0.05% fluticasone propionate cream twice daily to his left cheek and 1% pimecrolimus cream twice daily to his right cheek to determine effectiveness and his own preference. He returned 4 days later for reevaluation because of an erythematous papulopustular rosaceiform eruption confined to his right cheek where he had applied the 1% pimecrolimus cream. The dermatitis was noticeably absent from the contralateral cheek where the seborrheic dermatitis had mostly resolved. The rosaceiform dermatitis resolved approximately 7 days after cessation of the treatment with 1% pimecrolimus cream and initiation of 50 mg of minocycline hydrochloride twice daily. The patient denied any previous history of rosacea. No other studies or testing were performed.

×